Iressa

Biological Activity for Iressa

Technical Data for Iressa

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for Iressa

References for Iressa

References are publications that support the biological activity of the product.

• Y Merrouche, J Fabre, H Cure, C Garbar, C Fuselier, J Bastid, F Antonicell, R Al-Daccak, A Bensussan, J Giustinian IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells Oncotarget, 2016;7(33):53350-53361. 2016 PMID: 27462789
• A Stanley, GH Ashrafi, AM Seddon, H Modjtahedi Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines Sci Rep, 2017;7(1):3964. 2017 PMID: 28638122
• Zhou, Yan, Zhang, Yuanlian, Zou, Hanbing, Cai, Ning, Chen, Xiaojing, Xu, Longmei, Kong, Xianming, Liu, Peifeng The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells. Sci Rep, 2015;5(0):8629. 2015 PMID: 25720956
• Hsu Y, Gu F, Huang Y, Liu J, Ruan J, Huang R, Wang C, Chen C, Jadhav R, Lai H, Mutch D, Goodfellow P, Thompson I, Kirma N, Huang T Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res, 2013;19(22):6272-85. 2013 PMID: 24077349
• M Ishibashi, S Neri, H Hashimoto, T Miyashita, T Yoshida, Y Nakamura, H Udagawa, K Kirita, S Matsumoto, S Umemura, K Yoh, S Niho, M Tsuboi, K Masutomi, K Goto, A Ochiai, G Ishii CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors Sci Rep, 2017;7(0):46662. 2017 PMID: 28429795
• Smith A, Bowers S, Stratman A, Davis G Hematopoietic stem cell cytokines and fibroblast growth factor-2 stimulate human endothelial cell-pericyte tube co-assembly in 3D fibrin matrices under serum-free defined conditions. PLoS ONE, 2013;8(12):e85147. 2013 PMID: 24391990
• Khelwatty S, Essapen S, Seddon A, Fan Z, Modjtahedi H Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer, 2015;113(7):1010-9. 2015 PMID: 26372697
• Ciardiello et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin.Cancer Res., 2000;6:2053 PMID: 10815932
• Baselga et al. ZD1839 ('Iressa'), as an anticancer agent. Drugs, 2000;60:33 PMID: 11129170
• McKillop et al. Tumor penetration of gefi. (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol.Cancer Ther., 2005;4:641 PMID: 15827338
• Tan et al. Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlo. in a nude mouse model. Oncotarget., 2017;8:98771 PMID: 29228726